Seroprevalence of anti-SARS-CoV-2 antibodies after the second pandemic peak

Stringhini, Silvia; Zaballa, María-Eugenia; Perez-Saez, Javier; Pullen, Nick; Mestral, Carlos de; Picazio, A.; Pennacchio, Francesco; Wisniak, Ania; Richard, Aude; Baysson, Hélène; Loizeau, Andrea; Balavoine, Jean François; Trono, Didier; Pittet, Didier; Posfay‐Barbe, Klara M.; Flahault, Antoine; Chappuis, François; Kherad, Omar; Vuilleumier, Nicolas; Kaiser, Laurent; Azman, Andrew S.; Guessous, Idris

doi:10.1016/s1473-3099(21)00054-2

Cited by 68 publications

(77 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In Germany (April–June 2020), seropositivity was 0.97% using ELISA, and 0.36% using VNT [ 20 ]. Significantly higher seropositivity was observed after the second pandemic peak, varying from 11.4% in Poland (October–November 2020) [ 21 ], and 19.3% in Spain (Madrid, at the end of 2020) [ 22 ], to 21.1% in Switzerland (Geneva, November–December 2020) [ 23 ]. In Slovenia, the seroprevalence after the first (April 2020) and second (October–November 2020) waves was found to be 2.78% and 4.06%, respectively [ 24 ].…”

Section: Discussionmentioning

confidence: 99%

“…Compared with adults aged 25–34 years, children older than 6 years and adolescents had similar seroprevalence, whereas children aged 0–5 years were 43% less likely to be seropositive. Additionally, adults aged 65–74 years, and those older than 75 years, were 42% and 64% less likely to be SARS-CoV-2 seropositive [ 23 ]. Children and the elderly were probably less exposed to SARS-CoV-2 compared to young adults and the working-age population.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

SARS-CoV-2 Seroprevalence and Neutralizing Antibody Response after the First and Second COVID-19 Pandemic Wave in Croatia

et al. 2021

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel coronavirus with a pandemic spread. So far, a total of 349,910 SARS-CoV-2 cases and 7687 deaths were reported in Croatia. We analyzed the seroprevalence and neutralizing (NT) antibody response in the Croatian general population after the first (May–July 2020) and second (December 2020–February 2021) pandemic wave. Initial serological testing was performed using a commercial ELISA, with confirmation of reactive samples by a virus neutralization test (VNT). A significant difference in the overall seroprevalence rate was found after the first (ELISA 2.2%, VNT 0.2%) and second waves (ELISA 25.1%, VNT 18.7%). Seropositive individuals were detected in all age groups, with significant differences according to age. The lowest prevalence of NT antibodies was documented in the youngest (<10 years; 16.1%) and the oldest (60–69/70+ years; 16.0% and 12.8%, respectively) age groups. However, these age groups showed the highest median NT titers (32–64). In other groups, seropositivity varied from 19.3% to 21.5%. A significant weak positive correlation between binding antibody level as detected by ELISA and VNT titer (rho = 0.439, p < 0.001) was observed. SARS-CoV-2 NT antibody titers seem to be age-related, with the highest NT activity in children under 10 years and individuals above 50 years.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

SARS-CoV-2 Seroprevalence and Neutralizing Antibody Response after the First and Second COVID-19 Pandemic Wave in Croatia

et al. 2021

View full text Add to dashboard Cite

show abstract

“…In Switzerland, more than half a million individuals have been diagnosed with COVID-19, [34] and around 1.5 are estimated to have been infected according to current seroprevalence studies. [35] Based on our estimates of the proportion of infected individuals that suffer from longer-term complications, a relevant number of individuals may have to be expected to need some degree of support or healthcare services. In our study, we were able to provide more detail to the possible healthcare utilisation incurring due to COVID-19.…”

Section: Implications For Healthcare Resource Planningmentioning

confidence: 99%

Burden of Post-COVID-19 Syndrome and Implications for Healthcare Service Planning: A Population-based Cohort Study

Menges

Ballouz

Anagnostopoulos

et al. 2021

Preprint

View full text Add to dashboard Cite

ObjectiveTo assess the prevalence of impaired health status and physical and mental health symptoms among individuals at least six months after SARS-CoV-2 infection, and to characterise their healthcare utilisation.DesignPopulation-based prospective cohort study.SettingZurich SARS-CoV-2 Cohort, Zurich, Switzerland.Participants431 adults from the general population with PCR-confirmed SARS-CoV-2 infection reported to health authorities between 27 February 2020 and 05 August 2020.Main outcome measuresWe assessed the proportion of individuals reporting not having fully recovered since SARS-CoV-2 infection, the proportion reporting fatigue (assessed by Fatigue Assessment Scale), dyspnoea (assessed by mMRC dyspnoea scale) or depression (assessed by DASS-21) at six to eight months after diagnosis. We further evaluated the proportion of individuals with at least one healthcare contact since their acute illness. Multivariable logistic regression models were used to assess factors associated with the main outcomes.ResultsSymptoms were present in 385 (89%) participants at diagnosis and 81 (19%) were initially hospitalised. At six to eight months, 111 (26%) reported not having fully recovered. 233 (55%) participants reported symptoms of fatigue, 96 (25%) had at least grade 1 dyspnoea, and 111 (26%) had DASS-21 scores indicating symptoms of depression. 170 (40%) participants reported at least one general practitioner visit related to COVID-19 after acute illness, and 10% (8/81) of initially hospitalised individuals were rehospitalised. Individuals that have not fully recovered or suffer from fatigue, dyspnoea or depression were more likely to have further healthcare contacts. However, a third of individuals (37/111) that have not fully recovered did not seek further care.ConclusionIn our population-based study, a relevant proportion of individuals suffered from longer-term consequences after SARS-CoV-2 infection. Our findings indicate that a considerable number of individuals affected by post-COVID-19 syndrome is to be expected, and that a wide range of additional healthcare services and integrative approaches will be required to support the recovery of these individuals. Thus, the timely planning of resources and services for post-COVID-19 care will be necessary alongside public health measures to mitigate the effects of the pandemic.RegistrationISRCTN14990068

show abstract

“…We sampled from publicly available estimates of the daily effective reproduction number based on confirmed cases during the early growth phase of the variants in Geneva, Switzerland, ( 1November 2020 to 31 January 2021; range: 0.58-1.04) and South Africa (1 September 2020 to 31 October 2020; range: 0.90-1.12) (https://github.com/covid-19-Re) (Figure 1B) (Huisman et al, 2020). In Geneva, Switzerland, seroprevalence was estimated at 21.1% (95% credible interval: 19.2-23.1%; n = 4, 000) in samples collected from 23 November 2020 to 23 December 2020 (Figure 1C) (Stringhini et al, 2021). In South Africa, seroprevalence was estimated at 30.2% (95% CI: 28.8-31.2%; n = 4, 387) in samples collected from 17 August 2020 to 25 November 2020 (Shinde et al, 2021).…”

Section: /13mentioning

confidence: 99%

“…B: Effective reproduction number during the early growth phase of the variants (https://github.com/covid-19-Re)(Huisman et al, 2020). C: Seroprevalence estimates for Geneva, Switzerland(Stringhini et al, 2021), and South Africa(Shinde et al, 2021).…”

mentioning

confidence: 99%

A tale of two variants: Spread of SARS-CoV-2 variants Alpha in Geneva, Switzerland, and Beta in South Africa

Althaus

Baggio

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

Several SARS-CoV-2 variants of concern (VOC) are spreading rapidly in different regions of the world. The underlying mechanisms behind their transmission advantage remain unclear. We measured viral load in 950 individuals and found that infections with variant Alpha exhibit a higher viral load and longer viral shedding compared to non-VOC. We then used a transmission model to analyze the spread of variant Alpha in Geneva, Switzerland, and variant Beta in South Africa. We estimated that Alpha is either associated with a 37% (95% compatibility interval, CI: 25-63%) increase in transmissibility or a 51% (95% CI: 32-80%) increase of the infectious duration, or a combination of the two mechanisms. Assuming 50% immune evasion for Beta, we estimated a 23% (95% CI: 10-37%) increase in transmissibility or a 38% (95% CI: 15-78%) increase of the infectious duration for this variant. Beta is expected to outgrow Alpha in regions where the level of naturally acquired immunity from previously circulating variants exceeds 20% to 40%. Close monitoring of Alpha and Beta in regions with different levels of immunity will help to anticipate the global spread of these and future variants.

show abstract

Seroprevalence of anti-SARS-CoV-2 antibodies after the second pandemic peak

Cited by 68 publications

References 3 publications

SARS-CoV-2 Seroprevalence and Neutralizing Antibody Response after the First and Second COVID-19 Pandemic Wave in Croatia

SARS-CoV-2 Seroprevalence and Neutralizing Antibody Response after the First and Second COVID-19 Pandemic Wave in Croatia

Burden of Post-COVID-19 Syndrome and Implications for Healthcare Service Planning: A Population-based Cohort Study

A tale of two variants: Spread of SARS-CoV-2 variants Alpha in Geneva, Switzerland, and Beta in South Africa

Contact Info

Product

Resources

About